drugset
drugset / Trial / NCT06675565

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

NCT06675565 ↗

Phase 1 Completed 42 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.

Timeline

Start
2024-11-05
Primary completion
2025-09-08
Completion
2025-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ALN-AGT01 RVR Unknown — Subcutaneous

Indications

No indication recorded.